WO1996032178A1 - Leukocyte filtration method and apparatus - Google Patents

Leukocyte filtration method and apparatus Download PDF

Info

Publication number
WO1996032178A1
WO1996032178A1 PCT/US1996/003362 US9603362W WO9632178A1 WO 1996032178 A1 WO1996032178 A1 WO 1996032178A1 US 9603362 W US9603362 W US 9603362W WO 9632178 A1 WO9632178 A1 WO 9632178A1
Authority
WO
WIPO (PCT)
Prior art keywords
filter
cellulose
substrate
polysaccharide
membrane
Prior art date
Application number
PCT/US1996/003362
Other languages
French (fr)
Inventor
Menahem A. Kraus
Yephet Gamlieli
Jacob Yonath
Roni Hazan
Original Assignee
Travenol Laboratories (Israel) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Travenol Laboratories (Israel) Ltd. filed Critical Travenol Laboratories (Israel) Ltd.
Priority to DE69634829T priority Critical patent/DE69634829T2/en
Priority to EP96909670A priority patent/EP0869835B1/en
Priority to AU53093/96A priority patent/AU5309396A/en
Publication of WO1996032178A1 publication Critical patent/WO1996032178A1/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D67/00Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
    • B01D67/0081After-treatment of organic or inorganic membranes
    • B01D67/0088Physical treatment with compounds, e.g. swelling, coating or impregnation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D39/00Filtering material for liquid or gaseous fluids
    • B01D39/14Other self-supporting filtering material ; Other filtering material
    • B01D39/16Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres
    • B01D39/1607Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous
    • B01D39/1623Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous of synthetic origin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D67/00Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
    • B01D67/0081After-treatment of organic or inorganic membranes
    • B01D67/0093Chemical modification
    • DTEXTILES; PAPER
    • D06TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06MTREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M15/00Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
    • D06M15/01Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with natural macromolecular compounds or derivatives thereof
    • D06M15/03Polysaccharides or derivatives thereof
    • DTEXTILES; PAPER
    • D06TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06MTREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M15/00Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
    • D06M15/01Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with natural macromolecular compounds or derivatives thereof
    • D06M15/03Polysaccharides or derivatives thereof
    • D06M15/05Cellulose or derivatives thereof
    • DTEXTILES; PAPER
    • D06TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06MTREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M15/00Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
    • D06M15/01Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with natural macromolecular compounds or derivatives thereof
    • D06M15/03Polysaccharides or derivatives thereof
    • D06M15/05Cellulose or derivatives thereof
    • D06M15/09Cellulose ethers
    • DTEXTILES; PAPER
    • D06TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06MTREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M15/00Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
    • D06M15/01Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with natural macromolecular compounds or derivatives thereof
    • D06M15/03Polysaccharides or derivatives thereof
    • D06M15/11Starch or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/04Liquids
    • A61M2202/0413Blood
    • A61M2202/0427Platelets; Thrombocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/04Liquids
    • A61M2202/0413Blood
    • A61M2202/0439White blood cells; Leucocytes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2323/00Details relating to membrane preparation
    • B01D2323/30Cross-linking

Definitions

  • the present invention relates to methods of removing leukocytes from whole blood or platelet concentrates.
  • leukocytes may cause non- hemolytic febrile reactions and/or HLA allo-immunization. Leukocytes may also induce graft versus host reactions. In addition, leukocytes present in contaminated blood may harbor various viruses. At the same time, the removal of the leukocytes does not generally have negative implications for the recipient since the leukocytes serve no useful purpose in the vast majority of transfusions.
  • each portion of whole blood is typically first separated, e.g., by centrifuging and/or filtration, into a number of components or fractions, principally (1) packed erythrocytes (red blood cells); (2) platelet concentrate; and (3) plasma.
  • Each of the fractions then undergoes separate treatment, typically filtration, to remove the leukocytes present in that fraction. 6/32178 PCM- S96/03362
  • a difficulty with filters such as those disclosed in PCT US94/01413 is that they are limited to treatment of specific blood fractions rather than to whole blood. This limitation makes it necessary to carry out a number of separate filtrations, each using a specific filter, to separately remove the leukocytes from each of the blood fractions.
  • whole blood would then be filtered to remove leukocytes only once, preferably in the blood bank.
  • the leukocyte-free blood would be separated, as by centrifugation, into leukocyte-free fractions and processed in the usual
  • a method for selectively removing leukocytes from a suspension which also contains platelets comprising passing the suspension through a filter which includes a polysaccharide-type coating.
  • a filter for selectively removing leukocytes from a suspension which also contains platelets comprising: (a) a substrate; and (b) a coating on the substrate which includes a polysaccharide-type composition.
  • a process for preparing a filter for selectively removing leukocytes from a suspension which also contains platelets comprising the steps of: (a) providing a coating solution including a polysaccharide-type composition and a solvent; (b) applying the coating solution to a substrate; and (c) drying the coated substrate to form a dry coated substrate.
  • the polysaccharide-type composition includes one
  • hydroxypropyl cellulose hydroxyethyl cellulose, hydroxypropylmethyl cellulose, hydroxybutylmethyl cellulose, dextran and hydroxyethyl starch.
  • the present invention successfully addresses the shortcomings of the presently known configurations by providing a method and apparatus for efficiently selectively removing leukocytes from suspensions, such as blood and blood fractions, which also contain platelets.
  • the method and apparatus involves use of a membrane and/or non- woven material coated with a polysaccharide-type composition through
  • U.S. Patent 4,936,998 discloses the surface coating of preformed acrylic copolymers, such as copoly(hydroxyethyl methacrylate-diethylaminoethyl methacrylate).
  • U.S. Patent 4,880,548 discloses the grafting of certain monomers, such as acrylate, onto the surface. It is noted parenthetically that U.S. Patent No. 4,880,548 asserts that in order to obtain efficient platelet filtration a filter is required which features critical wetting surface tension of 90 dyn/cm or more.
  • Examples include various cellulose derivatives, including but not limited to, hydroxypropyl cellulose
  • HPC hydroxyethyl cellulose
  • HEC hydroxyethyl cellulose
  • HEC hydroxyethyl cellulose
  • HEC hydroxyethyl cellulose
  • HEC hydroxyethyl cellulose
  • HEC hydroxyethyl cellulose
  • HEC hydroxyethyl cellulose
  • HEC hydroxyethyl cellulose
  • HEC hydroxyethyl cellulose
  • HEC hydroxyethyl cellulose
  • HEC hydroxyethyl cellulose
  • HEC hydroxyethyl cellulose
  • HEC hydroxyethyl cellulose
  • HEC hyrdroxybutylmethyl cellulose
  • hyrdroxypropylmethyl cellulose dextran
  • hydroxyethyl starch hydroxyethyl starch
  • Preferred polysaccharide-type compositions include hydroxypropyl cellulose, hydroxypropylmethyl cellulose and hydroxybutylmethyl cellulose. The most
  • polysaccharide-type composition is hydroxypropyl cellulose.
  • the various polysaccharide-type compositions are generally soluble in water and a number of other solvents, such as ethanol.
  • a dilute solution, typically in water, of one or more of these polymers is used as a coating solution to coat the surface of the filter substrate or
  • a preferred solution is an aqueous HPC solution with an HPC concentration of from about 0.1 to about 10% wt/ vol. Most preferred is a concentration of from about 0.5 to about 3% wt/vol.
  • the filter substrate may be any suitable medium, preferably one or
  • the filter substrate includes both one or more non-woven sheets and one or more membranes.
  • the term 'membrane' is intended to include a continuous, nonfibrous porous matrix.
  • Membranes for use in the present invention may be made of any suitable material, including but not limited to, polycarbonate, acrylic copolymer, polyvinyl chloride, nylon and nitrocellulose.
  • suitable material including but not limited to, polycarbonate, acrylic copolymer, polyvinyl chloride, nylon and nitrocellulose.
  • membrane features a pore size of from about 2 to about 20 ⁇ .
  • Non-woven materials for use in the present invention may be made
  • any suitable material including but not limited to, polyester, cellulose, nylon and polypropylene.
  • a coating solution typically in water or ethanol, which
  • the filter substrate includes a polysaccharide composition is provided.
  • the filter substrate is then coated, as by dipping, with the coating solution.
  • the filter is then
  • composition and the substrate it may be desirable to provide a cross-linking agent in the coating solution.
  • a cross-linking agent Any suitable cross-linking agent may be used,
  • a melamine such as hexamethoxymethyl melamine, a polyepoxide, or a polyaldehyde.
  • the cross-linking agent reacts with the polysaccharide-type composition and renders it insoluble.
  • the cross-linking agent reacts with the polysaccharide-type composition and renders it insoluble.
  • the cross-linking agent reacts with the polysaccharide-type composition and renders it insoluble.
  • the substrate may also react with the substrate serving to bind the polysaccharide-type composition tightly to the substrate so as to preclude the possibility of the separation of the coating from the substrate.
  • a suitable washing medium such as water or ethanol
  • sufficient coating material may remain on the substrate to be effective.
  • the coating of the filter substrate as described above has been found to have a dramatic beneficial effect on platelet passage through the filter despite the fact that the coated substrate has a surface tension of only about 70 dyn/cm.
  • platelet recovery is typically from about 80 to about 100%.
  • the most preferred filter configuration includes two layers: (1) a non-
  • Each of the layers may include multiple filter sheets. Both layers are treated with the polysaccharide-type composition as described above.
  • Examples 1-23 relate to the filtration of platelet concentrates while Examples 24-28 relate to the filtration of whole blood.
  • Examples 11-15 Effect of the Concentration of the Coating Solution The coating effect is concentration dependent as shown in Table 3.
  • the model filters used were a combination of membranes and non- woven sheets.
  • HPC concentration of 0.5% (wt/vol) and higher ensures good flow, good platelet passage and little white cell leakage.
  • Nitrocellulose membrane AE100 (3 layers)
  • Filter treatment HPC coating
  • Examples 16-18 Effect of Coating Cross Linking
  • the filter coating was cross-linked for improved stability.
  • the cross- linking agent used was hexamethoxymethyl melamine. Table 4 summaries results from a number of treatment variables.
  • cross-linking alone or in conjunction with subsequent washing, apparently has little effect on either platelet or white cell passage.
  • the amount of extractable material lost upon washing is substantially reduced.
  • Full scale platelet filters suitable for 4 to 5 pooled units, were constructed from a layered structure of surface treated non-woven materials and treated membranes. Construction and performance data are summarized in Table 5.
  • HPC hydroxypropyl cellulose
  • the filter materials included nitroceUulos- membranes of nominal pore size 12 and 8 microns, and a 120g/m 2 non-woven polyester
  • the filter materials were dipped in the HPC solution for 5 minutes
  • the non- woven fabric was squeezed to remove excess solution.
  • the membranes were treated similarly, but were not squeezed.
  • the filter was constructed in a plastic holder of 43 cm 2 filtration area.
  • the filter was made up of two layers of 8 ⁇ membrane, two layers of 12 ⁇ membrane and 20 layers of non-
  • woven fabric were introduced between adjacent membranes to serve as separators. Four hundred seventy ml of whole blood were collected into a
  • Example 24 The procedure of Example 24 was repeated except that the 8 ⁇ membrane was omitted, and a 1% solution of HPC was used. In addition,
  • Example 26 Hydroxypropyl-methyl Cellulose Coating (Whole Blood) The same filter structure as in Example 24 was used for filtration of
  • Filtration rate was 470ml/33min. Leukocytes were reduced from 5600/ ⁇ l to 7/ ⁇ l and platelet recovery was 182000/ ⁇ l out of 216000/ ⁇ l in the
  • Example 26 The procedure of Example 26 was repeated except that four 12 ⁇ membranes were used and a 0.5% hydroxybutyl-methyl cellulose solution in a 9:1 water ethanol mixture was used as coating solution. No cross-linking
  • Example 26 The procedure of Example 26 was repeated using four 12 ⁇ membranes and a coating solution made up of a 1% hydroxyethyl cellulose aqueous solution containing 0.04% glyoxal as cross-linking agent. 530 ml of 6 hours old whole blood were filtered in 19 minutes. The leukocyte count was reduced from 6200/ ⁇ l to 300/ ⁇ l and platelet recovery was 45%.

Abstract

A method for selectively removing leukocytes from a suspension which also contains platelets, such as a platelet concentrate or whole blood. The method includes passing the suspension through a filter which includes a polysaccharide-type coating. The coating may include one or more of hydroxypropylmethyl cellulose, hydroxybutylmethyl cellulose, dextran and hydroxyethyl starch. Also provided is a filter for selectively removing leukocytes from a suspension which also contains platelets. The filter includes a substrate which is coated with a polysaccharide-type composition.

Description

LEUKOCYTE FILTRATION METHOD AND APPARATUS
FIELD AND BACKGROUND OF THE INVENTION
The present invention relates to methods of removing leukocytes from whole blood or platelet concentrates.
It is widely known that for the vast majority of transfusion therapies it is desirable to remove the leukocytes from donated blood, typically by filtration, prior to the transfusion of the various blood components into a
patient.
It is desirable to remove the leukocytes since their presence may have adverse effects on the patient. For example, leukocytes may cause non- hemolytic febrile reactions and/or HLA allo-immunization. Leukocytes may also induce graft versus host reactions. In addition, leukocytes present in contaminated blood may harbor various viruses. At the same time, the removal of the leukocytes does not generally have negative implications for the recipient since the leukocytes serve no useful purpose in the vast majority of transfusions.
The current practice is to remove the leukocytes from the various blood components after these have been separated from whole blood. Thus, each portion of whole blood is typically first separated, e.g., by centrifuging and/or filtration, into a number of components or fractions, principally (1) packed erythrocytes (red blood cells); (2) platelet concentrate; and (3) plasma. Each of the fractions then undergoes separate treatment, typically filtration, to remove the leukocytes present in that fraction. 6/32178 PCM- S96/03362
2
For example, in PCT/US94/01413 the present inventors describe unique, membrane-based Ωlters for removing leukocytes from packed red
blood cells or for removing both leukocytes and platelets from whole blood. The filters described in PCT/US94/01413 capture platelets and are thus unsuitable for the removal of leukocytes from platelet concentrates or from whole blood.
A difficulty with filters such as those disclosed in PCT US94/01413 is that they are limited to treatment of specific blood fractions rather than to whole blood. This limitation makes it necessary to carry out a number of separate filtrations, each using a specific filter, to separately remove the leukocytes from each of the blood fractions.
It would be advantageous to have an efficient filter capable of selectively removing leukocytes from whole blood, i.e., a filter which would effectively capture leukocytes while effectively passing the other blood components, including the plasma, red blood cells and the platelets.
The ability of selectively removing leukocytes from whole blood with the attendant recovery of red cells and platelets would have significant
operational and cost advantages. In practice, whole blood would then be filtered to remove leukocytes only once, preferably in the blood bank.
Following this filtration, the leukocyte-free blood would be separated, as by centrifugation, into leukocyte-free fractions and processed in the usual
manner.
The removal of leukocytes from whole blood requires a special filter
which captures leukocytes but passes red blood cells and platelets. Currently, no such filter is commercially available, although at least one such filter is described in the literature. Specifically, a whole blood leukocyte filter is disclosed in U.S. Patent No. 4,985,153. However the performance of that filter, as described in the above-referenced patent, is far from satisfactory, considering current internationally accepted standards. Current international standards call for residual leukocytes of no more than 5 x 106 per unit of blood. Platelet recovery is expected to be no less than 70%.
There is thus a need for, and it would highly advantageous to have, a universal filter exhibiting high platelet recovery and very high leukocyte retention.
SUMMARY OF THE INVENTION
According to the present invention there is provided a method for selectively removing leukocytes from a suspension which also contains platelets, comprising passing the suspension through a filter which includes a polysaccharide-type coating.
Also according to the present invention there is provided a filter for selectively removing leukocytes from a suspension which also contains platelets, comprising: (a) a substrate; and (b) a coating on the substrate which includes a polysaccharide-type composition.
Finally according to the present invention there is provided a process for preparing a filter for selectively removing leukocytes from a suspension which also contains platelets, comprising the steps of: (a) providing a coating solution including a polysaccharide-type composition and a solvent; (b) applying the coating solution to a substrate; and (c) drying the coated substrate to form a dry coated substrate.
According to further features in preferred embodiments of the invention described below, the polysaccharide-type composition includes one
or more of hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, hydroxybutylmethyl cellulose, dextran and hydroxyethyl starch.
The present invention successfully addresses the shortcomings of the presently known configurations by providing a method and apparatus for efficiently selectively removing leukocytes from suspensions, such as blood and blood fractions, which also contain platelets.
The method and apparatus involves use of a membrane and/or non- woven material coated with a polysaccharide-type composition through
which a suspension containing both leukocytes and platelets is passed. It has been found that this method and apparatus are effective in passing the platelets while retaining the leukocytes.
DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention is of a method and apparatus for efficiently
selectively removing leukocytes from whole blood or from a blood fraction which contains platelets.
The principles and operation of the present invention will be better understood with reference to the following description and examples. It is known in the literature that filtration can be used to recover platelets from leukocyte-free blood through the use of very specific surface treatments of the filter medium. In the absence of these treatments the filter will retain a large proportion of the platelets. Two types of such surface treatments are described in the literature.
U.S. Patent 4,936,998 discloses the surface coating of preformed acrylic copolymers, such as copoly(hydroxyethyl methacrylate-diethylaminoethyl methacrylate). U.S. Patent 4,880,548 discloses the grafting of certain monomers, such as acrylate, onto the surface. It is noted parenthetically that U.S. Patent No. 4,880,548 asserts that in order to obtain efficient platelet filtration a filter is required which features critical wetting surface tension of 90 dyn/cm or more.
None of the commercially available platelet concentrate leuko- depletion filters is suitable for recovery of platelets from whole blood since the presence of red blood cells along with platelets serves to rapidly clog these filters.
It has been unexpectedly found that coating of a suitable filter media using simple commercially available polysaccharides and polysaccharide derivatives (referred to herein singly and collectively as a "polysaccharide- type composition") makes it possible to construct highly efficient platelet filters which operate to remove leukocytes from platelet concentrates. Similar treatments can be used to make a highly efficient universal filter which efficiently removes leukocytes from whole blood. Thus, methods and filters according to the present invention are suitable for the removal of leukocytes, with minor modifications, for both platelet and whole blood
filtration.
Various polysaccharide-type compositions are suitable in a method
and filter according to the present invention. Examples include various cellulose derivatives, including but not limited to, hydroxypropyl cellulose
(HPC), hydroxyethyl cellulose (HEC), hyrdroxybutylmethyl cellulose, hyrdroxypropylmethyl, cellulose dextran and hydroxyethyl starch.
Preferred polysaccharide-type compositions include hydroxypropyl cellulose, hydroxypropylmethyl cellulose and hydroxybutylmethyl cellulose. The most
preferred polysaccharide-type composition is hydroxypropyl cellulose. The various polysaccharide-type compositions are generally soluble in water and a number of other solvents, such as ethanol.
A dilute solution, typically in water, of one or more of these polymers is used as a coating solution to coat the surface of the filter substrate or
medium. A preferred solution is an aqueous HPC solution with an HPC concentration of from about 0.1 to about 10% wt/ vol. Most preferred is a concentration of from about 0.5 to about 3% wt/vol.
The filter substrate may be any suitable medium, preferably one or
more non-woven sheets or one or more membranes. Most preferably, the filter substrate includes both one or more non-woven sheets and one or more membranes. As used herein, the term 'membrane' is intended to include a continuous, nonfibrous porous matrix.
Membranes for use in the present invention may be made of any suitable material, including but not limited to, polycarbonate, acrylic copolymer, polyvinyl chloride, nylon and nitrocellulose. Preferably, the
membrane features a pore size of from about 2 to about 20μ.
Non-woven materials for use in the present invention may be made
of any suitable material, including but not limited to, polyester, cellulose, nylon and polypropylene.
To produce a properly coated filter medium, typically membrane and/or non-woven, a coating solution, typically in water or ethanol, which
includes a polysaccharide composition is provided. The filter substrate is then coated, as by dipping, with the coating solution. The filter is then
dried at any suitable temperature, such as near room temperature or at elevated temperatures to evaporate the solvent and form a dry coated
substrate.
To provide for better bonding between the polysaccharide-type
composition and the substrate it may be desirable to provide a cross-linking agent in the coating solution. Any suitable cross-linking agent may be used,
including but not limited to a melamine, such as hexamethoxymethyl melamine, a polyepoxide, or a polyaldehyde. Upon drying the cross-linking
agent reacts with the polysaccharide-type composition and renders it insoluble. Depending on the substrate chemistry, the cross-linking agent
may also react with the substrate serving to bind the polysaccharide-type composition tightly to the substrate so as to preclude the possibility of the separation of the coating from the substrate.
Optionally, regardless of whether curing is used, it may be desirable to wash the dry coated substrate with a suitable washing medium, such as water or ethanol, and subsequently re-dry the washed coated substrate. Even in the absence of cross-linking, sufficient coating material may remain on the substrate to be effective.
The coating of the filter substrate as described above has been found to have a dramatic beneficial effect on platelet passage through the filter despite the fact that the coated substrate has a surface tension of only about 70 dyn/cm.
Whereas many untreated filter media, such as polyester, nylon, nitrocellulose, with pore size of 2-20 μm retain all or a very significant
fraction of the platelets, following treatment with a polysaccharide-type composition, platelet recovery is typically from about 80 to about 100%.
While at times the retention of white cells is also slightly reduced by the treatment, the effect is not nearly as pronounced as the increase in platelet recovery. In this way, a good separation between leukocytes and platelets can be achieved.
Because of their flexible membrane and poor adhesion, red cells pass easily through filters of the present invention. Thus, a universal filter,
which is able to selectively remove leukocytes from all other blood components is achieved. As demonstrated in the examples below, with the appropriate number and porosity of layers of filter media, highly efficient leukocyte-removing filters for platelet concentrates and for whole blood can be constructed.
The most preferred filter configuration includes two layers: (1) a non-
woven filter layer and a membrane filter layer. Each of the layers may include multiple filter sheets. Both layers are treated with the polysaccharide-type composition as described above. A typical filter, made
as described, yields platelets recovery of greater than 70% and leukocyte
retention of greater than 99% in both platelet concentrate filtration and whole blood filtration.
EXAMPLES Examples 1-23 relate to the filtration of platelet concentrates while Examples 24-28 relate to the filtration of whole blood.
Examples 1-6: Effect of Coating on Membrane Performance
Various membranes were treated by dipping into a solution of 1% hydroxypropyl cellulose (HPC) in water. The membranes were then allowed
to dry at ambient conditions. The treated membranes and untreated controls were tested for passage of platelets and white blood cells from standard platelet concentrates. The results are summarized in Table 1. As can be clearly seen, the treatment dramatically improves platelet passage and flow rate. Table 1: Filtration of Platelet Concentrates (PC) Through Coated Membrane Filters
Ex. Membrane Pore Treatment No. of Flow Cell Passage size Layers Rate
(μm) ml/min PLT% WBC%
1 Polycarbonate 2 Untreated 1 0 0 0 (PC, Poretics) Coated 1 0.3 100 30
2 Acrylic 3 Untreated 1 0 1 0 copolymer Coated 1 0.5 75 17 (Versapore, Gelman)
3 PVC (GLA- 5 Untreated 1 0 0 0 5000, Gelman) Coated 1 0.3 32 0
4 Nylon (Magna- 10 Untreated 1 0.1 13 0 Nylon, MSI) Coated 1 0.8 75 14
5 Nylon (Magna- 20 Untreated 1 0.9 77 32 Nylon, MSI) Coated 2 3.8 96 11
6 Nitrocellulose 12 Untreated 2 0.7 32 18 (NC, AE100, Coated 2 9.0 92 13 S&S)
Examples 7-10: Effect of Coating on Non-woven Filter
Performance
Various Polyester non-woven filters were treated by dipping the filter substrate in 1% aqueous or ethanol HPC solution and drying.
Multilayer arrays of treated filters and untreated controls were used to filter platelet concentrates. The results are summarized in Table 2.
It is clearly seen that the passage of platelets is very substantially improved following treatment, while the passage of white cells increases to a much smaller extent. Table 2: Filtration of Platelets Concentrates Through Coated Non- wovens
Example Filter Treatment No. of Flow Cell Passage Layers Rate ml/min PLT% WBC%
7 Polyester Untreated 10 86 55 15 80 g/m2, Coated 10 40 100 35 Sodoca Coated 30 6 94 5
8 Polyester Untreated 10 7 24 9 100 g/m2, Coated 10 3 100 29 Sodoca
9 Polyester Untreated 10 3* 19 0 120 g/m2, Coated 10 3* 86 9 Freudenberg
10 Cellulose llμ Untreated 6 0.7 83 20 (Whatman) Coated 6 2 96 40
* Flow adjusted to 3 ml/min.
Examples 11-15: Effect of the Concentration of the Coating Solution The coating effect is concentration dependent as shown in Table 3. The model filters used were a combination of membranes and non- woven sheets.
As shown, HPC concentration of 0.5% (wt/vol) and higher ensures good flow, good platelet passage and little white cell leakage.
SUBSTTTUTE SHEET (RULE 26) Table 3: Effect of HPC Coating Concentration on Filter Performance
Filter Composition: Polyester 120g/m2 Sheets (6 layers)
Nitrocellulose membrane: AE100 (3 layers) Filter treatment: HPC coating
Flow Rate: Adjusted to 1.0-1.5 ml/min
Example HPC Concen. Vol. (ml) Cell Passage
(%) Filtered Before Clogging PLT% WBC%
11 0 < 6 9 2
12 0.25 < 23 79 4
13 0.5 > 30 84 5
14 1.0 > 30 85 3
15 2.0 > 30 89 5
Examples 16-18: Effect of Coating Cross Linking The filter coating was cross-linked for improved stability. The cross- linking agent used was hexamethoxymethyl melamine. Table 4 summaries results from a number of treatment variables.
It is shown that cross-linking, alone or in conjunction with subsequent washing, apparently has little effect on either platelet or white cell passage. However, the amount of extractable material lost upon washing is substantially reduced.
SUBSTTTUTE SHEET (RULE 26) Table 4: Cell Separation Following Various Filter Treatments
Filter composition: Polyester 120g/m2 sheet (8 layers) and AE (3 layers)
Example Filter and Cell Passage Treatment
PLT% WBC%
16 2% HPC 89 3
17 2% HPC + 87 2 Cross Linking
18 2% HPC + 88 2 Cross Linking + Washing
Examples 19-23: Full Scale Platelet Filters
Full scale platelet filters, suitable for 4 to 5 pooled units, were constructed from a layered structure of surface treated non-woven materials and treated membranes. Construction and performance data are summarized in Table 5.
SUBSTTTUTE SHEET (RULE 26) Table 5: Performance of Full Scale Platelet Filters
Ex. Filter No. of Vol. Platelet WBC Residual WBC Composition Layers Filtered Recovery Removal
(ml) (%) (%) per μl Total
19 Polyester 80g/m2 32 200 98 99.95 0.25 O.lxlO6 AE-100 (12μ) 3
20 Polyester 100g/m2 20 250 94 99.83 1.1 0.25xl06
AE-100 (12μ) 4
21 Polyester 100g/m2 16 200 95 99.74 1.4 0.27x10*
AE-100 (12μ) 5
22 Polyester 100g/m2 20 200 100 99.70 1.6 0.32xl06
AE-100 (12μ) 5
23 Polyester 100g/m2 20 230 88 99.81 1.1 0.25x10*
AE-100 (12μ) 5
Treatment a. Filters 19 and 21 - coating (1% HPC) b. Filters 20 and 22 - coating and cross-linking (0.025% melamine) c. Filter 23 - coating, cross-linking and washing
Example 24: Hydroxypropyl Cellulose Coating (Whole Blood)
A 0.1% aqueous solution of hydroxypropyl cellulose (HPC) of 370000
MW was used. The filter materials included nitroceUulos- membranes of nominal pore size 12 and 8 microns, and a 120g/m2 non-woven polyester
fabric.
The filter materials were dipped in the HPC solution for 5 minutes
at room temperature. The non- woven fabric was squeezed to remove excess solution. The membranes were treated similarly, but were not squeezed.
After 24 hours of drying at room temperature a filter was constructed in a plastic holder of 43 cm2 filtration area. The filter was made up of two layers of 8μ membrane, two layers of 12μ membrane and 20 layers of non-
woven fabric serving as a pre-filter. Another four layers of the same non-
woven fabric were introduced between adjacent membranes to serve as separators. Four hundred seventy ml of whole blood were collected into a
standard collection bag using CPD anticoagulation solution and filtered 6 hours after donation. Filtration time was 27 minutes at a pressure head of 0.09 atm. Leukocyte content was reduced from 6300/μl in the original blood
to 4/μl in the filtered blood. Seventy two percent of the original platelets
(185000/μ) were recovered. The erythrocyte content of the filtered blood was reduced by only 0.5%. When the same experiment was repeated without applying HPC coating to the filter layers only 1-5% of the platelets were recovered.
Example 25: Effect of Washing (Whole Blood)
The procedure of Example 24 was repeated except that the 8μ membrane was omitted, and a 1% solution of HPC was used. In addition,
after the dip-coated membranes and pre-filters were dried, they were washed by soaking in water at 22°C for 20 min. Twenty hours old whole 6/32178 PCMJS96/03362
16 blood was filtered in this system at a rate of 485 ml/11 min. Leukocyte
reduction was from 5000/μl to 15/μl. Platelet recovery was 216000/μl out of
282000/μl in the original blood.
Repeating this experiment without applying the HPC coating resulted
in only a 1-5% platelet recovery.
Example 26: Hydroxypropyl-methyl Cellulose Coating (Whole Blood) The same filter structure as in Example 24 was used for filtration of
6 hours old whole blood. Coating was performed using a 0.6% aqueous solution of hydroxypropyl-methyl cellulose (M.W. 86000; hydroxypropyl content: 10%, methyl content: 30%) containing 0.016% glyoxal as cross- linking agent. After dipping, membranes and pre-filters were baked at 108- 115°C for 40 minutes, washed and dried as per Example 25.
Filtration rate was 470ml/33min. Leukocytes were reduced from 5600/μl to 7/μl and platelet recovery was 182000/μl out of 216000/μl in the
original blood.
Example 27: Hydroxybutyl-methyl Cellulose Coating (Whole Blood)
The procedure of Example 26 was repeated except that four 12μ membranes were used and a 0.5% hydroxybutyl-methyl cellulose solution in a 9:1 water ethanol mixture was used as coating solution. No cross-linking
agent was used, and the baking and washing steps were omitted. Four hundred forty ml of whole blood were filtered in 25 minutes. Platelet recovery was 73%, and leukocyte content was reduced from 7800/μl .to
300/μl. Example 28: Hydroxyethyl Cellulose Coating (Whole Blood)
The procedure of Example 26 was repeated using four 12μ membranes and a coating solution made up of a 1% hydroxyethyl cellulose aqueous solution containing 0.04% glyoxal as cross-linking agent. 530 ml of 6 hours old whole blood were filtered in 19 minutes. The leukocyte count was reduced from 6200/μl to 300/μl and platelet recovery was 45%.
While the invention has been described with respect to a limited number of embodiments, it will be appreciated that many variations, modifications and other applications of the invention may be made.

Claims

WHAT IS CLAIMED IS:
1. A method for selectively removing leukocytes from a suspension which also contains platelets, comprising: passing the suspension through a filter which includes a polysaccharide-type coating.
2. The method of claim 1, wherein said polysaccharide-type coating includes one or more species selected from the group consisting of
hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, hydroxybutylmethyl cellulose, dextran and hydroxyethyl starch.
3. The method of claim 1, wherein said polysaccharide-type coating includes hydroxypropyl cellulose.
4. A filter for selectively removing leukocytes from a suspension which also contains platelets, comprising:
(a) a substrate; and
(b) a coating on said substrate which includes a polysaccharide- type composition.
5. The filter of claim 4, wherein said polysaccharide-type
composition includes one or more species selected from the group consisting of hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, hydroxybutylmethyl cellulose, dextran and hydroxyethyl starch.
6. The filter of claim 4, wherein said polysaccharide-type
composition includes hydroxypropyl cellulose.
7. The filter of claim 4, wherein said substrate includes at least one membrane.
8. The filter of claim 4, wherein said substrate includes at least one non- woven material.
9. The filter of claim 8, wherein said substrate further includes at least one membrane.
10. The filter of claim 7, wherein said membrane has a pore size
of from about 2 to about 20μ.
11. The filter of claim 7, wherein said membrane includes material selected from the group consisting of polycarbonate, acrylic copolymer,
polyvinyl chloride, nylon, nitrocellulose and cellulose esters.
12. The filter of claim 8, wherein said non-woven material is a polyester. 6/32178 POYUS96.03362
20
13. A process of preparing a filter for selectively removing
leukocytes from a suspension which also contains platelets, comprising the steps of:
(a) providing a coating solution including a polysaccharide-type composition and a solvent;
(b) applying said coating solution to a substrate; and
(c) drying said coated substrate to form a dry coated substrate.
14. The process of claim 13, wherein said coating solution further
includes a cross-linking agent.
15. The process of claim 14, wherein said cross-linking agent is selected from the group consisting of melamine, polyepoxide and
polyaldehyde.
16. The process of claim 13, wherein said polysaccharide-type composition includes one or more of the species selected from the group consisting of hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, hydroxybutylmethyl cellulose, dextran and
hydroxyethyl starch.
17. The process of claim 13, wherein said polysaccharide-type
composition includes hydroxypropyl cellulose.
18. The process of claim 13, wherein the concentration of said hydroxypropyl cellulose in said solvent is from about 0.1 to about 10%
(wt/vol).
19. The process of claim 13, wherein the concentration of said hydroxypropyl cellulose in said solvent is from about 0.5 to about 3%
(wt/vol).
20. The process of claim 13, wherein said substrate includes at least one membrane.
21. The process of claim 13, wherein said substrate includes at least one non- woven material.
22. The process of claim 21, wherein said substrate further includes at least one membrane.
23. The process of claim 20, wherein said membrane has a pore size of from about 2 to about 20μ.
24. The process of claim 20, wherein said membrane includes
material selected from the group consisting of polycarbonate, acrylic copolymer, polyvinyl chloride, nylon and nitrocellulose.
25. The process of claim 21, wherein said non-woven material is a polyester.
26. The process of claim 13, further comprising:
(d) washing said dry coated substrate; and
(e) drying said washed coated substrate.
PCT/US1996/003362 1995-04-13 1996-03-12 Leukocyte filtration method and apparatus WO1996032178A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE69634829T DE69634829T2 (en) 1995-04-13 1996-03-12 METHOD AND DEVICE FOR LEUKOCYTE FILTRATION
EP96909670A EP0869835B1 (en) 1995-04-13 1996-03-12 Leukocyte filtration method and apparatus
AU53093/96A AU5309396A (en) 1995-04-13 1996-03-12 Leukocyte filtration method and apparatus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42227495A 1995-04-13 1995-04-13
US08/422,274 1995-04-13

Publications (1)

Publication Number Publication Date
WO1996032178A1 true WO1996032178A1 (en) 1996-10-17

Family

ID=23674146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/003362 WO1996032178A1 (en) 1995-04-13 1996-03-12 Leukocyte filtration method and apparatus

Country Status (6)

Country Link
US (2) US5783094A (en)
EP (1) EP0869835B1 (en)
AU (1) AU5309396A (en)
DE (1) DE69634829T2 (en)
IL (1) IL117482A (en)
WO (1) WO1996032178A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020622A1 (en) * 1995-12-07 1997-06-12 Gkss-Forschungszentrum Geesthacht Gmbh Composite nanofiltration membrane
FR2774293A1 (en) * 1998-02-05 1999-08-06 Maco Pharma Sa PLASMA TRANSFORMATION PROCESS AND DEVICE FOR IMPLEMENTING SAME
KR100229579B1 (en) * 1997-06-04 1999-11-15 박호군 Leucocyte removing filter coated with modified chitosan
EP1445012A1 (en) * 2003-02-04 2004-08-11 LS medcap GmbH Filter device
EP1506808A1 (en) * 2003-07-31 2005-02-16 Teva Medical Ltd. Leukocyte filter and method of use
US8864725B2 (en) 2009-03-17 2014-10-21 Baxter Corporation Englewood Hazardous drug handling system, apparatus and method

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010075549A (en) * 1998-10-02 2001-08-09 와이너 길버트 피. Biological fluid filter and system
US6274041B1 (en) 1998-12-18 2001-08-14 Kimberly-Clark Worldwide, Inc. Integrated filter combining physical adsorption and electrokinetic adsorption
US6537614B1 (en) 1998-12-18 2003-03-25 Kimberly-Clark Worldwide, Inc. Cationically charged coating on hydrophobic polymer fibers with poly (vinyl alcohol) assist
AU3376400A (en) * 1999-02-25 2000-09-14 Pall Corporation Negatively charged membrane
US6783937B1 (en) * 1999-02-25 2004-08-31 Pall Corporation Negatively charged membrane
EP1473075B1 (en) * 1999-02-25 2015-07-29 Pall Corporation Negatively charged membrane
ATE260697T1 (en) * 1999-03-17 2004-03-15 Foster Miller Inc SENSITIVE GELS AND METHODS OF USE THEREOF
US6645388B2 (en) 1999-12-22 2003-11-11 Kimberly-Clark Corporation Leukocyte depletion filter media, filter produced therefrom, method of making same and method of using same
IL137077A (en) * 2000-06-28 2003-05-29 Teva Medical Ltd Leukoreduction filter
US6612447B1 (en) * 2000-07-24 2003-09-02 Baxter International Inc. Blood collection systems and filters using a porous membrane element
US6780309B2 (en) * 2002-03-22 2004-08-24 Allegiance Corporation Tapered hydrophobic filter for suction canisters
US6709868B2 (en) * 2002-05-20 2004-03-23 Portascience Inc. Method and apparatus for measuring white blood cell count
ITTO20030039A1 (en) * 2003-01-24 2004-07-25 Fresenius Hemocare Italia Srl FILTER TO SEPARATE LEUKOCYTES FROM WHOLE BLOOD AND / OR FROM BLOOD-PREPARED PROCEDURES, PROCEDURE FOR FILTER MANUFACTURE, DEVICE AND USE.
US8828226B2 (en) 2003-03-01 2014-09-09 The Trustees Of Boston University System for assessing the efficacy of stored red blood cells using microvascular networks
ITMI20031715A1 (en) * 2003-09-05 2005-03-06 Dideco Spa CONTROL DEVICE IN THE DIFFERENTIATED COLLECTION OF THE
US7060018B2 (en) 2003-09-11 2006-06-13 Cobe Cardiovascular, Inc. Centrifuge apparatus for processing blood
US7807823B2 (en) * 2004-02-05 2010-10-05 Millipore Corporation Method of forming polysaccharide structures
US7687619B2 (en) 2004-02-05 2010-03-30 Millipore Corporation Room temperature stable agarose solutions
EP2821124A1 (en) * 2004-02-05 2015-01-07 EMD Millipore Corporation Method of forming coated structures
US7479223B2 (en) 2004-02-05 2009-01-20 Millipore Corporation Porous adsorptive or chromatographic media
US7479222B2 (en) * 2004-02-05 2009-01-20 Millipore Corporation Porous adsorptive or chromatographic media
US7853546B2 (en) * 2007-03-09 2010-12-14 General Electric Company Enhanced rule execution in expert systems
US9433922B2 (en) * 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
US20090130738A1 (en) * 2007-11-19 2009-05-21 Mikhail Kozlov Media for membrane ion exchange chromatography
EP2620139B1 (en) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1 receptor antagonist rich solutions
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
JP2013507447A (en) 2009-10-12 2013-03-04 ニュー ヘルス サイエンシーズ、インク. Oxygen depletion device and method for removing oxygen from red blood cells
US8535421B2 (en) 2009-10-12 2013-09-17 New Health Sciences, Inc. Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities
US9339025B2 (en) 2010-08-25 2016-05-17 New Health Sciences, Inc. Method for enhancing red blood cell quality and survival during storage
EP2611456A2 (en) 2010-09-03 2013-07-10 Biomet Biologics, LLC Methods and compositions for delivering interleukin-1 receptor antagonist
EP4218412A1 (en) 2010-11-05 2023-08-02 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
WO2013023156A1 (en) 2011-08-10 2013-02-14 New Health Sciences, Inc. Integrated leukocyte, oxygen and/or co2 depletion, and plasma separation filter device
EP2941642B1 (en) 2013-01-03 2020-05-13 Brigham and Women's Hospital, Inc. System and method for a biomimetic fluid processing
EP3967143A1 (en) 2013-02-28 2022-03-16 Hemanext Inc. Gas addition device for blood treatment and corresponding method
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
JP6332602B2 (en) * 2014-02-18 2018-05-30 東洋紡株式会社 Hydrophilic polymer nonwoven fabric sheet
US10376627B2 (en) 2014-03-24 2019-08-13 Fenwal, Inc. Flexible biological fluid filters
US10159778B2 (en) 2014-03-24 2018-12-25 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US9968738B2 (en) 2014-03-24 2018-05-15 Fenwal, Inc. Biological fluid filters with molded frame and methods for making such filters
US9796166B2 (en) 2014-03-24 2017-10-24 Fenwal, Inc. Flexible biological fluid filters
US9782707B2 (en) 2014-03-24 2017-10-10 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US10590373B2 (en) * 2014-03-31 2020-03-17 Brigham And Women's Hospital, Inc. Systems and methods for biomimetic fluid processing
US10111610B2 (en) 2014-11-04 2018-10-30 Wainamics, Inc. Microscale plasma separator
AU2016228993B2 (en) 2015-03-10 2022-02-10 Hemanext Inc. Oxygen reduction disposable kits, devices and methods of use thereof
IL285359B2 (en) 2015-04-23 2024-01-01 Hemanext Inc Anaerobic blood storage containers
EP3297641A4 (en) 2015-05-18 2019-02-06 New Health Sciences, Inc. Methods for the storage of whole blood, and compositions thereof
PT3463466T (en) 2016-05-27 2022-04-04 Hemanext Inc Anaerobic blood storage and pathogen inactivation method
US11266988B2 (en) 2017-03-20 2022-03-08 Wainamics, Inc. Small volume self-metered blood separation device
CN107213806B (en) * 2017-07-13 2018-03-06 广州达济医学科技有限公司 A kind of filter membrane for filtrating leukocytes and preparation method thereof
TWI715998B (en) * 2019-01-28 2021-01-11 笙特科技股份有限公司 Filter material and manufacturing method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416777A (en) * 1979-10-09 1983-11-22 Asahi Kasei Kogyo Kabushiki Kaisha Separation of leukocytes or lymphocytes from leukocyte-containing suspension
US4744907A (en) * 1987-01-16 1988-05-17 Interferon Sciences, Inc. Blood cell separation
US4880548A (en) * 1988-02-17 1989-11-14 Pall Corporation Device and method for separating leucocytes from platelet concentrate
US5053133A (en) * 1990-02-09 1991-10-01 Elias Klein Affinity separation with activated polyamide microporous membranes
US5091086A (en) * 1986-08-27 1992-02-25 Danisco A/S Permeable, porous polymeric membrane with hydrophilic character, methods for preparing said membranes and their use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255256A (en) * 1978-12-13 1981-03-10 Antonio Ferrante Medium for the separation of human blood leucocytes
US4413074A (en) * 1982-01-25 1983-11-01 Brunswick Corporation Hydrophilic surfaces and process for making the same
CH660852A5 (en) * 1982-11-23 1987-05-29 Aligena Ag DYNAMIC MEMBRANES THAT ARE THIN THIN POLYMER LAYERS ON POROUS, POLYMER CARRIER MATERIALS.
US4936998A (en) * 1986-03-28 1990-06-26 Asahi Medical Co., Ltd. Filter medium for selectively removing leucocytes
US4964989A (en) * 1986-12-23 1990-10-23 Pall Corporation Membranes with low protein adsorbability
JPH0726959B2 (en) * 1988-01-20 1995-03-29 富士写真フイルム株式会社 Whole blood analysis element
US5286449A (en) * 1988-04-04 1994-02-15 Asahi Medical Co., Ltd. Adsorber module for whole blood treatment and an adsorber apparatus containing the adsorber module
AU617265B2 (en) * 1988-06-23 1991-11-21 Asahi Medical Co. Ltd. Method for separating blood into blood components, and blood components separator unit
JP2864035B2 (en) * 1989-02-09 1999-03-03 富士写真フイルム株式会社 Whole blood analysis element
DE69231566T2 (en) * 1991-08-22 2001-06-21 Asahi Medical Co FILTER MEDIUM FOR SELECTIVE REMOVAL OF LEUKOCYTES AND APPROPRIATE DEVICE
JP3383962B2 (en) * 1992-02-28 2003-03-10 ニプロ株式会社 Leukocyte removal filter
US5460777A (en) * 1992-03-16 1995-10-24 Fuji Photo Film Co., Ltd. Analytical element for whole blood analysis
US5407581A (en) * 1992-03-17 1995-04-18 Asahi Medical Co., Ltd. Filter medium having a limited surface negative charge for treating a blood material
IL104670A (en) * 1993-02-09 1998-04-05 Travenol Lab Israel Ltd Leukocyte removal method and filter unit for same
JP3167508B2 (en) * 1993-06-15 2001-05-21 富士写真フイルム株式会社 Inorganic phosphorus determination reagent and dry analytical element
US5456835A (en) * 1993-11-08 1995-10-10 Hemasure, Inc. Device and process for removing free hemoglobin from blood

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416777A (en) * 1979-10-09 1983-11-22 Asahi Kasei Kogyo Kabushiki Kaisha Separation of leukocytes or lymphocytes from leukocyte-containing suspension
US5091086A (en) * 1986-08-27 1992-02-25 Danisco A/S Permeable, porous polymeric membrane with hydrophilic character, methods for preparing said membranes and their use
US4744907A (en) * 1987-01-16 1988-05-17 Interferon Sciences, Inc. Blood cell separation
US4880548A (en) * 1988-02-17 1989-11-14 Pall Corporation Device and method for separating leucocytes from platelet concentrate
US5053133A (en) * 1990-02-09 1991-10-01 Elias Klein Affinity separation with activated polyamide microporous membranes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0869835A4 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020622A1 (en) * 1995-12-07 1997-06-12 Gkss-Forschungszentrum Geesthacht Gmbh Composite nanofiltration membrane
KR100229579B1 (en) * 1997-06-04 1999-11-15 박호군 Leucocyte removing filter coated with modified chitosan
FR2774293A1 (en) * 1998-02-05 1999-08-06 Maco Pharma Sa PLASMA TRANSFORMATION PROCESS AND DEVICE FOR IMPLEMENTING SAME
WO1999039758A1 (en) * 1998-02-05 1999-08-12 Maco Pharma Method for transforming plasma and implementing device
EP1445012A1 (en) * 2003-02-04 2004-08-11 LS medcap GmbH Filter device
EP1506808A1 (en) * 2003-07-31 2005-02-16 Teva Medical Ltd. Leukocyte filter and method of use
US8864725B2 (en) 2009-03-17 2014-10-21 Baxter Corporation Englewood Hazardous drug handling system, apparatus and method

Also Published As

Publication number Publication date
EP0869835B1 (en) 2005-06-08
DE69634829D1 (en) 2005-07-14
EP0869835A4 (en) 1998-11-25
EP0869835A1 (en) 1998-10-14
IL117482A0 (en) 1996-08-04
AU5309396A (en) 1996-10-30
US5895575A (en) 1999-04-20
DE69634829T2 (en) 2006-03-23
IL117482A (en) 2000-02-29
US5783094A (en) 1998-07-21

Similar Documents

Publication Publication Date Title
US5783094A (en) Whole blood and platelet leukocyte filtration method
AU724497B2 (en) Leukocyte-removing filter medium
US4936998A (en) Filter medium for selectively removing leucocytes
US5665233A (en) Filter apparatus for selectively removing leukocytes
US5476587A (en) Leukocyte-separating filter and leukocytes remover
US5707520A (en) Remover unit for use in filtration circuit for removing at least leukocyte
IL104670A (en) Leukocyte removal method and filter unit for same
US7524425B2 (en) Filter for the removal of substances from blood products
WO2001032236A1 (en) Filter for selectively removing leukocyte
EP1016426A1 (en) Leukocyte-removing filter material
Bruil et al. Asymmetric membrane filters for the removal of leukocytes from blood
CN107213806B (en) A kind of filter membrane for filtrating leukocytes and preparation method thereof
JP3172542B2 (en) Filter material for capturing leukocytes and method for producing the same
JP3741320B2 (en) Leukocyte selective removal filter material
US6193896B1 (en) Method for removal of leucocytes from blood
JP3270125B2 (en) Leukocyte trapping material
WO1989002304A1 (en) Leucocyte-separating filter
JP3250833B2 (en) Leukocyte selective capture filter material
US20040178140A1 (en) Filtering device
WO1989002305A1 (en) Leucocyte-separating filter
JP3273061B2 (en) Leukocyte and platelet capture filters
JP2002085551A (en) Leukocyte removing filter material
JP2002238996A (en) Leukocyte-removing filter device and leukocyte-removing method
JP2001347116A (en) White blood cell removing filter device
JPH05245198A (en) Leucocyte capturing body and its production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996909670

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWP Wipo information: published in national office

Ref document number: 1996909670

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1996909670

Country of ref document: EP